Single Center-Based Real-World Experience on Anti-IL 1 Biological Response Modifiers: A Case Series and Literature Review

Overview

Journal Children (Basel)

Specialty Health Services

Date 2024 Sep 28

PMID 39334678

Authors

Olcay Y Jones

Affiliations

Soon will be listed here.

Abstract

Background: This communication summarizes our single-center experience with the use of anti-IL-1 biologic response modifiers for treating autoimmune and autoinflammatory conditions in children.

Methods: We outline our rationale for the off-label use of anakinra and discuss emerging treatment paradigms that necessitate further research and validation.

Results: Anakinra has enabled personalized treatment, whether used as a single agent on an as-needed basis, as part of a background treatment regimen, or in combination with colchicine. Our data also highlight the significance of anakinra in treating post-infectious inflammatory diseases, demonstrating its high efficacy in novel applications such as rheumatic fever and post-viral arthritis. Canakinumab, on the other hand, has provided long-term remission. Both medications were well-tolerated, with no serious adverse effects reported.

Conclusions: Based on our observations and successful outcomes, we advocate for future collaborative efforts to improve access to anti-IL-1 medications to better manage excessive and harmful inflammation in children.

References

McMurray J, May J, Cunningham M, Jones O . Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitis-A Critical Review of Its Pathogenesis and Treatment. Front Pediatr. 2021; 8:626182. PMC: 7793714. DOI: 10.3389/fped.2020.626182. View

Norheim K, Harboe E, Goransson L, Omdal R . Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial. PLoS One. 2012; 7(1):e30123. PMC: 3254637. DOI: 10.1371/journal.pone.0030123. View

Jumah H, Kundrapu S, Jabri A, Kondapaneni M, Tomashefski J, Loeffler A . Cardiac macrophage density in Covid-19 infection: relationship to myocyte necrosis and acute lung injury. Cardiovasc Pathol. 2022; 60:107447. PMC: 9212794. DOI: 10.1016/j.carpath.2022.107447. View

Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M . Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis. 2004; 64(4):630-3. PMC: 1755442. DOI: 10.1136/ard.2004.025858. View

Cron R . Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children. Curr Opin Rheumatol. 2022; 34(5):274-279. DOI: 10.1097/BOR.0000000000000889. View

Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I . Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020; 2(7):e393-e400. PMC: 7259909. DOI: 10.1016/S2665-9913(20)30164-8. View

Maniscalco V, Abu-Rumeileh S, Mastrolia M, Marrani E, Maccora I, Pagnini I . The off-label use of anakinra in pediatric systemic autoinflammatory diseases. Ther Adv Musculoskelet Dis. 2020; 12:1759720X20959575. PMC: 7580132. DOI: 10.1177/1759720X20959575. View

Dinarello C, van der Meer J . Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013; 25(6):469-84. PMC: 3953875. DOI: 10.1016/j.smim.2013.10.008. View

Grayson P, Yazici Y, Merideth M, Sen H, Davis M, Novakovich E . Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study. Arthritis Res Ther. 2017; 19(1):69. PMC: 5364674. DOI: 10.1186/s13075-017-1222-3. View

10.

Zitoun N, Demirkaya E, Goldbach-Mansky R, Romano M . Time for a new approach to drug development for rare systemic autoinflammatory diseases. Nat Rev Rheumatol. 2024; 20(6):317-318. DOI: 10.1038/s41584-024-01108-6. View

11.

Tegtmeyer K, Atassi G, Zhao J, Maloney N, A Lio P . Off-Label studies on anakinra in dermatology: a review. J Dermatolog Treat. 2020; 33(1):73-86. DOI: 10.1080/09546634.2020.1755417. View

12.

Dein E, Ingolia A, Connolly C, Manno R, Timlin H . Anakinra for Recurrent Fevers in Systemic Lupus Erythematosus. Cureus. 2019; 10(12):e3782. PMC: 6395019. DOI: 10.7759/cureus.3782. View

13.

Romano M, Arici Z, Piskin D, Alehashemi S, Aletaha D, Barron K . The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated.... Ann Rheum Dis. 2022; 81(7):907-921. DOI: 10.1136/annrheumdis-2021-221801. View

14.

Ferrara G, Giani T, Caparello M, Farella C, Gamalero L, Cimaz R . Anakinra for Treatment-Resistant Kawasaki Disease: Evidence from a Literature Review. Paediatr Drugs. 2020; 22(6):645-652. PMC: 7471561. DOI: 10.1007/s40272-020-00421-3. View

15.

Jesus A, Goldbach-Mansky R . IL-1 blockade in autoinflammatory syndromes. Annu Rev Med. 2014; 65:223-44. PMC: 4178953. DOI: 10.1146/annurev-med-061512-150641. View

16.

Arnold D, Yalamanoglu A, Boyman O . Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders. Front Immunol. 2022; 13:888392. PMC: 9296857. DOI: 10.3389/fimmu.2022.888392. View

17.

Dinarello C . Overview of the interleukin-1 family of ligands and receptors. Semin Immunol. 2013; 25(6):389-93. DOI: 10.1016/j.smim.2013.10.001. View

18.

Loncharich M, Klusewitz S, Jones O . Post-COVID-19 Multisystem Inflammatory Syndrome in Children and Adults: What Happens After Discharge?. Cureus. 2022; 14(4):e24438. PMC: 9128763. DOI: 10.7759/cureus.24438. View

19.

Salek-Ardakani S, Lyons S, Arrand J . Epstein-Barr virus promotes human monocyte survival and maturation through a paracrine induction of IFN-alpha. J Immunol. 2004; 173(1):321-31. DOI: 10.4049/jimmunol.173.1.321. View

20.

Bianco F, Bucciarelli V, Coretti F, Cataldi S, Damadei F, Raffaelli E . Serial cardiac magnetic resonance imaging for guidance of therapy management in patients treated with anakinra due to recurrent pericarditis. Eur Heart J Imaging Methods Pract. 2024; 2(1):qyae019. PMC: 11195722. DOI: 10.1093/ehjimp/qyae019. View